Bimagrumab vs Semaglutide
Muscle-Building Antibody vs GLP-1 — and Why They Pair Up (2026)
Bimagrumab and semaglutide are not really rivals — they do almost opposite things. Semaglutide (Ozempic/Wegovy) is a GLP-1 that drives weight loss by cutting appetite, but some of that loss is muscle. Bimagrumab is an antibody that builds muscle while reducing fat. The most interesting data uses them together.
Bimagrumab vs Semaglutide: At a Glance
- ✓Monoclonal antibody — blocks activin type II receptors
- ✓Builds lean muscle while reducing fat mass
- ✓Periodic infusion/injection (roughly monthly)
- ✓Investigational for obesity (Eli Lilly / Versanis)
- ✓Designed to complement a GLP-1, not replace it
- ✓Targets the muscle-loss weakness of GLP-1 therapy
- ✓GLP-1 receptor agonist — suppresses appetite
- ✓Strong total weight loss, but some is lean mass
- ✓Weekly injection (Wegovy/Ozempic) or daily pill
- ✓FDA-approved and widely available
- ✓Proven cardiovascular benefit (SELECT)
- ✓The fat-loss engine bimagrumab is paired with
Detailed Comparison
| Feature | Bimagrumab | Semaglutide |
|---|---|---|
| Drug Class | ActRII antibody | GLP-1 receptor agonistBest |
| Primary Effect | Builds muscle, reduces fat | Reduces appetite → weight loss |
| Effect on Muscle | Increases lean mass | Can reduce lean mass |
| Administration | Periodic infusion/injection | Weekly injection or daily pill |
| Manufacturer | Eli Lilly (Versanis) | Novo Nordisk |
| Status (obesity) | Investigational | FDA-approved |
| Best Used | As an add-on for body composition | As primary weight-loss therapy |
| Key Data | BELIEVE combo: 92% of loss from fat | STEP 1: 14.9% weight loss at 68 wks |
The BELIEVE Combination Data
Why This Isn't Really "vs"
Comparing bimagrumab and semaglutide head-to-head misses the point: they act on different tissues. Semaglutide is the proven, approved engine of weight loss — it cuts appetite and drives the scale down. Its weakness is that a meaningful fraction of the loss can be muscle. Bimagrumab does the opposite job: it builds muscle and trims fat, but it is not a primary appetite-driven weight-loss drug.
That is exactly why the BELIEVE trial combined them. Together, they produced 22% total weight loss with 92% from fat and only 2.9% lean-mass loss — better body composition than semaglutide alone. The future this points to is not "pick one" but "GLP-1 for fat loss + a muscle agent to protect lean mass."
For now, semaglutide is what you can actually get; bimagrumab is investigational. If muscle loss on a GLP-1 worries you today, the proven levers are adequate protein and resistance training. Track your weight, strength, and measurements in Shotlee so you can see whether you are losing fat — or muscle.
Bimagrumab vs Semaglutide: Frequently Asked Questions
They do different things, so neither is simply "better." Semaglutide is a proven, approved GLP-1 that drives weight loss via appetite. Bimagrumab is an investigational antibody that builds muscle and cuts fat. The strongest data uses them together.
That combination is exactly what the Phase 2 BELIEVE trial studied — it produced 22% weight loss with 92% from fat and strong muscle preservation. But bimagrumab is investigational for obesity and not yet available for clinical use.
GLP-1 weight loss includes some lean-mass loss — by some analyses up to roughly 40% of total weight lost. Adequate protein and resistance training help. Bimagrumab is being developed specifically to counter this.
No. Bimagrumab is investigational for obesity and not available by prescription for weight loss. Semaglutide is FDA-approved and widely available.
Eat enough protein, do resistance training, and track your body composition. Shotlee lets you log weight, measurements, and protein alongside your doses to catch lean-mass loss early.
Track Fat Loss vs Muscle in Shotlee
Free tracking for weight, measurements, protein, and GLP-1 doses — so your loss comes from fat, not muscle.